Wednesday, October 7, 2026
← Back to archivePolicy
Policy•KFF•Oct 6, 2026
Midterm Election Update: Vaccines
background ▾
- •Federal childhood vaccination recommendations reduced by 35% (17 to 11 diseases) and routine vaccines cut by 46% (13 to 7), positioning the U.S. as an outlier among developed nations and fundamentally altering the immunization framework that has governed U.S. pediatric practice for decades
- •Six previously routine vaccines now require individual clinical decision-making rather than universal recommendation, and voluntary reporting replaces mandatory Medicaid/CHIP vaccination tracking, severely compromising disease surveillance and herd immunity monitoring
- •Measles resurgence and declining vaccination rates are already occurring; monitor state-level vaccination mandate challenges, payer coverage decisions, vaccine manufacturer demand forecasts, and potential disease outbreak escalation in underimmunized populations
COVID-19 vaccinesRotavirus vaccineInfluenza vaccine
→ Read original articlePolicy•Endpoints News•Oct 6, 2026
Utah steps up AI prescribing
background ▾
- •Utah is establishing itself as a regulatory leader in healthcare AI policy, potentially influencing national standards for AI in prescribing and clinical practice
- •State-level AI policy initiatives may create new frameworks that pharmaceutical companies must navigate for digital health and prescribing tools
Policy•Endpoints News•Oct 6, 2026
In DC, a secretive new thorn has appeared in pharma's side
background ▾
- •Undisclosed or opaque advocacy organizations with tenuous public profiles are emerging as potential vehicles for pharmaceutical industry influence in DC policy discussions
- •The article suggests growing concern among pharma observers about non-transparent lobbying tactics, though specific policy outcomes or regulatory changes are not detailed
Policy•STAT News•Oct 6, 2026
Opinion: Infectious disease expert: The mysterious pneumonia in Russia deserves attention, not panic
background ▾
- •No confirmed plague diagnosis or evidence of sustained transmission—current facts do not support pandemic emergence speculation
- •Cause of death remains officially undetermined, and conflicting reports plus an unusually extensive public health response justify legitimate questions about transparency and laboratory safety protocols
Policy•Fierce Biotech•Oct 6, 2026
How NIH’s Nicole Kleinstreuer is working to reduce animal testing while avoiding a ‘backlash’
background ▾
- •NIH is systematically prioritizing human-based research technologies and computational approaches over animal models, positioning this as a top strategic priority under current NIH leadership
- •FDA Modernization Act 3.0 (passed July 2024) now directs the FDA to formally update its regulations to reflect the removal of mandatory animal testing for investigational drugs, creating regulatory tailwinds for NAM adoption
- •Watch for: adoption rates of NAMs in NIH grant portfolios, regulatory acceptance of alternative methods by FDA, and industry resistance or momentum in drug development timelines as the policy takes effect
National Institutes of Health (NIH)FDA
→ Read original articleMarket Access
Market Access•Fierce Biotech•Oct 6, 2026
CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline
background ▾
- •Allogeneic CAR-T sector is experiencing a "nuclear winter" in funding as investor capital flows to in vivo gene-editing approaches, making it economically unviable for Caribou to complete development despite clinically competitive data
- •Vispa-cel demonstrated safety and efficacy parity with Bristol Myers Squibb's Breyanzi and Kite's Yescarta in phase 1, with FDA agreement on phase 3 design—a significant setback for patients and the field given the therapy's readiness
- •Watch for: asset acquisitions by well-capitalized pharma firms, potential rescue of Caribou's programs by companies like Allogene, and whether the capital drought in allogeneic CAR-T signals broader biotech sector consolidation and investor reallocation
Caribou BiosciencesBristol Myers SquibbKite Pharmavispa-celCB-011Breyanzi
→ Read original articleMarket Access•Fierce Biotech•Oct 6, 2026
Abbott nabs FDA approval for new CardioMEMS HF System that allows heart readings to be seen at home
background ▾
- •Abbott's CardioMEMS system now offers direct patient access to PAP readings via smartphone app, enhancing engagement and earlier detection of worsening heart failure before symptomatic presentation
- •Dynamic Treatment Plan feature enables clinician-directed medication adjustments sent automatically to patients, creating a closed-loop monitoring and treatment adjustment system
- •Competitive advantage over Boston Scientific's HeartLogic: CardioMEMS uses minimally invasive catheter implantation versus surgical ICD/CRT-D implantation, potentially broadening eligible patient population
AbbottBoston ScientificCardioMEMS HF SystemCardioGuide HF AppHeartLogic
→ Read original articleMarket Access•STAT News•Oct 7, 2026
Opinion: My oncologist recommended active surveillance for prostate cancer. Life insurers called it ‘untreated cancer’
background ▾
- •Life insurers routinely classify low-risk prostate cancer managed by active surveillance as 'untreated cancer,' denying or severely restricting coverage despite this being the standard-of-care recommendation from urologic oncologists.
- •Insurance underwriting criteria appear misaligned with current clinical evidence and professional guidelines that support active surveillance for Gleason 6 (Grade Group 1) prostate cancer, creating a financial penalty for patients following evidence-based treatment.
- •The insurance industry's risk assessment practices have not evolved to reflect decades of clinical experience showing that low-risk prostate cancer with stable PSA rarely escapes the prostate, suggesting a need for payer education or policy reform around active surveillance strategies.
Market Access•Endpoints News•Oct 6, 2026
KymaThera, Rouge raise VC funding; Vaxcyte, Spyre do public offerings
background ▾
- •KymaThera secured $80M Series B funding for K-1728 development, demonstrating sustained VC interest in PI3K inhibitors
KymaTheraRougeVaxcyteK-1728
→ Read original articleMarket Access•Endpoints News•Oct 6, 2026
Forbion gets Lilly's backing in Dutch VC's largest-ever fundraising haul
background ▾
- •Forbion secured €2.3 billion in its largest-ever fundraising, signaling robust VC appetite for life sciences investment despite market headwinds
ForbionEli Lilly
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Oct 6, 2026
ArriVent’s phase 3 lung cancer trial flops, sinking stock
background ▾
- •Firmonertinib failed to meet its primary PFS endpoint by BICR (11 vs 9.5 months), eliminating the chemotherapy-free positioning versus Rybrevant, a critical commercial and clinical differentiation factor.
- •Investigator-assessed PFS favored firmonertinib (11.1 vs 7.1 months) and response rates were strong (60% vs 33%), but BICR is the standard for regulatory decision-making, making these secondary findings unlikely to rescue the program without robust OS benefit.
- •Overall survival data remain immature; positive OS results are the only near-term path to salvaging firmonertinib's development, but the PFS failure substantially increases regulatory and commercial risk for this NSCLC indication.
ArriVent BioPharmaJohnson & JohnsonfirmonertinibRybrevant
→ Read original articleClinical Trials•Fierce Biotech•Oct 6, 2026
Kairos seizes moment to push prostate cancer prospect into earlier setting
background ▾
- •Interim data showed ENV-105 combined with apalutamide achieved 17.7-month median PFS versus 2 months with apalutamide alone, demonstrating a potentially transformative benefit in castration-resistant prostate cancer
- •Protocol amendment to earlier treatment setting expands eligible patient population and should improve trial enrollment, a critical advantage for a cash-constrained biotech
- •Watch for Q4 2025 trial completion and regulatory pathway decisions; monitor Kairos' funding situation as $2.6M cash may be insufficient for operations
Kairos PharmaAstellasPfizerENV-105Xtandiapalutamide
→ Read original articleClinical Trials•Fierce Biotech•Oct 6, 2026
Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune disease
background ▾
- •NVG-2089 CIDP trial halted after enrolling only 14 patients since April 2025 launch due to enrollment challenges and economics, not safety
- •Company remains committed to the program and is pursuing alternative indications; ITP trial continues with data expected imminently
- •Competitive landscape in rare autoimmune space has intensified with recent approvals (Vyvgart Hytrulo, HyQvia), potentially influencing resource allocation decisions
Nuvig TherapeuticsBristol Myers SquibbSanofiNVG-2089Vyvgart HytruloHyQvia
→ Read original articleClinical Trials•Fierce Biotech•Oct 6, 2026
Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
background ▾
- •Mimetic's SLiP functions as a 'bait molecule' that outcompetes ankyrin-3 binding to Nav1.8, reducing channel surface expression—a mechanistic approach distinct from allosteric inhibition used by competitors like Vertex
- •The company has progressed from the prototype SLiP to multiple candidates currently in evaluation, indicating advancement beyond single-target validation
- •Watch for Mimetic's transition to IND-enabling studies and first-in-human trials; competitive positioning against Vertex's Journeyax and emerging psychedelic therapies will clarify market opportunity
Mimetic MedicinesVertex PharmaceuticalsJournavxpregabalinduloxetine
→ Read original articleClinical Trials•Endpoints News•Oct 6, 2026
AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
background ▾
- •Epkinly demonstrated efficacy in first-line DLBCL, a substantially larger market than relapsed/refractory DLBCL, directly challenging Polivy's established position
- •The trial success validates the T-cell engager class in frontline settings and sets up a multi-competitor landscape in DLBCL
- •Watch for regulatory submissions and timelines; comparative efficacy/safety profiles and payer positioning will determine market share dynamics
AbbVieGenmabGileadEpkinlyepcoritamabPolivy
→ Read original article